Ascentage Pharma Appoints Mr. Yiqing Chen as Chief Financial

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...

Related Keywords

China , Australia , Shanghai , Hong Kong , Rockville , Western Australia , Suzhou , Jiangsu , Dajun Yang , Ascentage Pharma , Prnewswire Ascentage Pharma , Fosun Pharma , Major National , China Europe International Business School , Expert Committee For South China , Department Of Food Science Engineering , Md Anderson Cancer Center , Institute Of Management Accountants , Shanghai Jiao Tong University , Astrazeneca , Ernst Young , Dana Farber Cancer Institute , Association Of Chartered Certified Accountants , Yiqing Chen , Chief Financial Officer , Chief Executive Officer , General Manager , Investor Relations , Capital Deployment , Deputy General Manager , Initial Public Offering , Investment Banking , Citi Orient Securities , Deputy Director , Orient Securities , Certified Public Accountant , Chartered Institute , Management Accountants , Chartered Global Management Accountant , Chartered Certified Accountants , Food Science , New Wealth Management , Main Board , Stock Exchange , Hong Kong Limited , Major National Rd Projects , Major New Drug Projects , New Drug Incubator , Innovative Drug Programs , Major Project , New Drug Application , Priority Review , Breakthrough Therapy , Orphan Drug Designation , Fast Track Designation , Cancer Center , Mayo Clinic ,